Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2007 1
2008 1
2009 1
2010 1
2013 1
2015 4
2016 8
2017 8
2018 5
2019 6
2020 6
2021 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Plasma free Hemoglobin for detecting centrifugal pump thrombosis.
Kuroda T, Mutsuga M, Yamada M, Yamakawa M, Yuhara S, Hasegawa H, Yokote J, Yokoyama Y, Yamada T, Koyama T, Usui A. Kuroda T, et al. Among authors: hasegawa h. Perfusion. 2021 Sep;36(6):620-625. doi: 10.1177/0267659120957183. Epub 2020 Sep 10. Perfusion. 2021. PMID: 32909509
Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. Yamashita T, et al. Among authors: hasegawa h. Trials. 2020 Jun 8;21(1):503. doi: 10.1186/s13063-020-04408-w. Trials. 2020. PMID: 32513251 Free PMC article.
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. Yamashita T, et al. Among authors: hasegawa h. Trials. 2020 May 7;21(1):391. doi: 10.1186/s13063-020-04341-y. Trials. 2020. PMID: 32381018 Free PMC article. Clinical Trial.
43 results